Published in Discov Med on April 01, 2015
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther (2016) 0.84
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
Epigenetics and Genetics of Viral Latency. Cell Host Microbe (2016) 0.79
Gene Editing for Treatment of Neurological Infections. Neurotherapeutics (2016) 0.76
Application of CRISPR/Cas9 Technology to HBV. Int J Mol Sci (2015) 0.76
Novel AIDS therapies based on gene editing. Cell Mol Life Sci (2017) 0.75
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
Recent advances in Japanese encephalitis. F1000Res (2017) 0.75
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
Negative Feedback Regulation of HIV-1 by Gene Editing Strategy. Sci Rep (2016) 0.75
Drugs in Development for Hepatitis B. Drugs (2017) 0.75
Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet (1971) 12.13
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet (1970) 11.61
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet (2011) 9.88
Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell (1985) 7.17
Cas9 as a versatile tool for engineering biology. Nat Methods (2013) 6.87
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res (2013) 6.19
DNA of a human hepatitis B virus candidate. J Virol (1974) 5.90
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 4.41
Human papillomavirus 1a complete DNA sequence: a novel type of genome organization among papovaviridae. EMBO J (1982) 4.13
Mechanisms of human papillomavirus-induced oncogenesis. J Virol (2004) 3.95
Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol (2014) 3.72
CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell (2014) 3.68
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods (2014) 3.34
Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc Natl Acad Sci U S A (1975) 3.26
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell (2014) 3.16
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma. J Virol (2007) 2.68
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol (2014) 2.51
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32
Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods (2012) 2.07
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene (1993) 1.91
A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol (2015) 1.83
Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.76
Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene (2006) 1.71
Replication of EBV in epithelial cells during infectious mononucleosis. Nature (1977) 1.61
Insertion and deletion mutants of FokI restriction endonuclease. J Biol Chem (1994) 1.48
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41
CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J (2014) 1.34
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nat Commun (2014) 1.31
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev (2001) 1.27
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol (2014) 1.26
Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians (2000) 1.22
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther (2015) 1.17
The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol Life Sci (2009) 1.17
CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16
CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol (2014) 1.12
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
Targeted gene disruption to cure HIV. Curr Opin HIV AIDS (2013) 1.09
HPV E6, E6AP and cervical cancer. BMC Biochem (2008) 1.08
Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07
The role of miRNAs and EBV BARTs in NPC. Semin Cancer Biol (2011) 1.06
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
TALEN-mediated genome editing: prospects and perspectives. Biochem J (2014) 1.01
Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev (2014) 0.93
Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther (2013) 0.93
Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res (2003) 0.90
Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology (2015) 0.90
Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int (2014) 0.87
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
Genome engineering using Adeno-Associated Virus (AAV). Methods Mol Biol (2015) 0.82
Integrase-deficient lentivirus: opportunities and challenges for human gene therapy. Curr Gene Ther (2014) 0.82
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol (2004) 2.20
Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol (2008) 1.82
HIV-1 associated dementia: symptoms and causes. Retrovirology (2006) 1.70
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J Natl Cancer Inst (2002) 1.69
Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke (2002) 1.66
Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res (2006) 1.63
Regulation of gene expression in primate polyomaviruses. J Virol (2009) 1.61
Astrocyte-elevated gene-1 (AEG-1) induction by hypoxia and glucose deprivation in glioblastoma. Cancer Biol Ther (2011) 1.61
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and beta-catenin. Cancer Res (2002) 1.54
Protective role of Puralpha to cisplatin. Cancer Biol Ther (2008) 1.44
Pathogenesis of progressive multifocal leukoencephalopathy--revisited. J Infect Dis (2011) 1.43
Development of a bidirectional caspase-3 expression system for the induction of apoptosis. Cancer Biol Ther (2008) 1.42
Integrating role of T antigen, Rb2/p130, CTCF and BORIS in mediating non-canonical endoplasmic reticulum-dependent death pathways triggered by chronic ER stress in mouse medulloblastoma. Cell Cycle (2012) 1.41
Role of Purα in the cellular response to ultraviolet-C radiation. Cell Cycle (2010) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Multiple roles for Puralpha in cellular and viral regulation. Cell Cycle (2009) 1.39
IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci U S A (2010) 1.36
JC virus-induced changes in cellular gene expression in primary human astrocytes. J Virol (2003) 1.36
Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol (2004) 1.28
BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol (2011) 1.27
HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis (2007) 1.24
CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells. FASEB J (2010) 1.23
Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem (2009) 1.21
Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene (2002) 1.21
Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol (2015) 1.21
Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol (2003) 1.21
Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology (2004) 1.21
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J (2007) 1.20
Evidence for BAG3 modulation of HIV-1 gene transcription. J Cell Physiol (2007) 1.20
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol (2008) 1.19
Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene (2002) 1.19
Functional interaction between JC virus late regulatory agnoprotein and cellular Y-box binding transcription factor, YB-1. J Virol (2002) 1.17
Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res (2002) 1.15
Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. Cancer (2005) 1.15
Role of JC virus agnoprotein in DNA repair. J Virol (2004) 1.14
Gi-coupled receptors mediate phosphorylation of CPI-17 and MLC20 via preferential activation of the PI3K/ILK pathway. Biochem J (2006) 1.14
Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome. J Virol (2004) 1.13
Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol (2011) 1.13
Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem (2010) 1.13
Tubulin-mediated binding of human immunodeficiency virus-1 Tat to the cytoskeleton causes proteasomal-dependent degradation of microtubule-associated protein 2 and neuronal damage. J Neurosci (2006) 1.12
Phosphorylation mutants of JC virus agnoprotein are unable to sustain the viral infection cycle. J Virol (2006) 1.12
Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther (2009) 1.10
Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy. J Neuroimmunol (2010) 1.10
Alterations of DNA damage repair pathways resulting from JCV infection. Virology (2007) 1.10
The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog (2013) 1.10
Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation. Lab Invest (2008) 1.10
Class III beta-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J Neuropathol Exp Neurol (2008) 1.09
Human polyomavirus JCV late leader peptide region contains important regulatory elements. Virology (2006) 1.09
T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol (2006) 1.08
Expression of JC virus regulatory proteins in human cancer: potential mechanisms for tumourigenesis. Eur J Cancer (2005) 1.08
Effect of HIV-1 Vpr on cell cycle regulators. DNA Cell Biol (2004) 1.08
Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer (2008) 1.08
Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging (2006) 1.08
Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol (2005) 1.07
Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes. J Biol Chem (2004) 1.07
Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol (2004) 1.06
JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis. J Virol (2007) 1.05
Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol (2004) 1.05
Modulation of JC virus transcription by C/EBPbeta. Virus Res (2009) 1.05
Early growth response-1 protein is induced by JC virus infection and binds and regulates the JC virus promoter. Virology (2008) 1.05
Human polyomaviruses and brain tumors. Brain Res Brain Res Rev (2005) 1.04
Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol (2002) 1.03
Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Virology (2003) 1.03
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
Interaction between JCV large T-antigen and beta-catenin. Oncogene (2004) 1.03
Dephosphorylation of JC virus agnoprotein by protein phosphatase 2A: inhibition by small t antigen. Virology (2008) 1.02
Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am J Pathol (2007) 1.02
Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol (2006) 1.02
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors. Oncogene (2004) 1.01
Evidence for phosphatase activity of p27SJ and its impact on the cell cycle. J Cell Biochem (2009) 1.01
HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis. PLoS One (2013) 1.01
Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region. Anticancer Res (2007) 1.01
Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen. J Biol Chem (2002) 1.00
Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene (2003) 1.00
Regulation of human neurotropic JC virus replication by alternative splicing factor SF2/ASF in glial cells. PLoS One (2011) 0.99
Nuclear factor kappa B signaling initiates early differentiation of neural stem cells. Stem Cells (2012) 0.99
Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis (2004) 0.99
BAG3: a new player in the heart failure paradigm. Heart Fail Rev (2015) 0.98
An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol (2003) 0.98
MH2 domain of Smad3 reduces HIV-1 Tat-induction of cytokine secretion. J Neuroimmunol (2006) 0.98
Cooperativity between Rad51 and C/EBP family transcription factors modulates basal and Tat-induced activation of the HIV-1 LTR in astrocytes. J Cell Physiol (2006) 0.98
Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol (2008) 0.98
Regulation of human polyomavirus JC virus gene transcription by AP-1 in glial cells. J Virol (2003) 0.98
Members of the AP-1 family, c-Jun and c-Fos, functionally interact with JC virus early regulatory protein large T antigen. J Virol (2003) 0.96
Evidence for involvement of transforming growth factor beta1 signaling pathway in activation of JC virus in human immunodeficiency virus 1-associated progressive multifocal leukoencephalopathy. Arch Pathol Lab Med (2004) 0.96
p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28. Mol Cell Biol (2005) 0.96
JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol (2006) 0.96
Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors--medulloblastomas. J Neurovirol (2002) 0.96
Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother (2003) 0.96
Reciprocal transactivation between HIV-1 and other human viruses. Virology (2006) 0.96
BAG3 protein regulates caspase-3 activation in HIV-1-infected human primary microglial cells. J Cell Physiol (2009) 0.95
Interplay between cdk9 and NF-kappaB factors determines the level of HIV-1 gene transcription in astrocytic cells. Oncogene (2002) 0.95
Epigenetic regulation of polyomavirus JC. Virol J (2013) 0.95
BAG3 expression in glioblastoma cells promotes accumulation of ubiquitinated clients in an Hsp70-dependent manner. J Biol Chem (2011) 0.95
Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother (2003) 0.95